Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Enrollment completed in phase IIb study of treatment for female sexual arousal disorder
January 19th, 2006
Vivus Inc. (VVUS) announced it completed enrollment in its phase IIb clinical study of its investigational drug Alista(topical alprostadil), for the treatment of female sexual arousal disorder (FSAD). This phase IIb trial is a multi-center, randomized, double blind, placebo-controlled study to evaluate the safety and efficacy of Alista. The primary endpoint is the increase in the number of satisfactory sexual encounters per month during the 24-week treatment period relative to the initial 8-week baseline period. The trial will also measure changes in arousal and distress associated with the patients' FSAD. Over 300 women who have undergone a hysterectomy and who have...
Source: Women's Health Weekly (2006-01-19)
|
